Pfizer Throws Down $7.3B Gauntlet in Obesity Race with Metsera Buyout
After internal setbacks, Pfizer is buying its way into the obesity drug market.
Industry Trends
FDA’s BsUFA III Framework: What It Means for Biosimilar Sponsors
FDA defines biosimilar PAS & CBE under BsUFA III
Focus Brief: Market Access Weekly September 1 to 7, 2025
Global market access shifts: HTA speed, UK pricing, digital disruption.
The Big Bet: Health Care Deal Spotlight for September 1 to 7, 2025)
Healthcare deal spotlight September 1 to 7, 2025
NCPE Recommends Conditional Access for Omeprazole
NCPE recommends Omeprazole Appizped for reimbursement eligibility.
NCPE Recommends Vabysmo, Signaling Retinal Policy Shift
NCPE recommends Vabysmo for neovascular (wet) age-related macular degeneration treatment.
Kymera Strikes License Agreement Deals With Sanofi, Gilead
Sanofi, Gilead sign License Agreement with Kymera for protein degrader programs.
New Reimbursement Strategy Boosts Ambulatory Pay
New partnership advances reimbursement strategy for private practices.
Judge Rules ReWalk Device Is Medically Necessary for Medicare
Medicare exoskeleton coverage approved for ReWalk Personal Exoskeleton, sets key precedent.
Vor Bio and RemeGen Seal $4B Global License Agreement
Vor Bio, RemeGen sign Global License Agreement for RC98 development.